We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




International Effort to Develop Personalized Treatments for Liver Diseases

By LabMedica International staff writers
Posted on 21 Apr 2011
A multinational consortium has been formed to advance research leading to personalized treatment of liver diseases including hepatitis B and C.

Roche Diagnostics (Basel, Switzerland) will be cooperating with the Vall d'Hebron Institute of Research (Barcelona, Spain), the Networking Biomedical Research Center in Liver and Digestive Diseases (CIBEREHD; Barcelona, Spain), and the software producer Advanced Biological Laboratories Therapy Edge (Luxembourg) in a study designed to resolve the current limitations that prevent the individualization of anti-HBV and anti-HCV (hepatitis B and C) treatments. More...
CIBERHED comprises eight Spanish research groups, specialized in liver biology and disease.

The project, which is aimed at identifying methods for personalized treatment of liver diseases in ways that will minimize healthcare costs and patient side effects, will be based on Roche's 454 Sequencing Systems. The other participants will contribute bioinformatics analysis and other genetic and molecular analytical techniques.

"The hepatitis C and B viruses exhibit great variability; a person infected with one of these viruses presents a complex population of variants comprising a structure known as "quasispecies,” said Dr. Juan Ignacio Esteban-Mur, head of liver disease treatment at the Vall d'Hebron Institute of Research. "The identification of these variants may be crucial for avoiding the selection of variants resistant to the new antiviral therapies.”

Related Links:
Roche Diagnostics
Vall d'Hebron Institute of Research
Networking Biomedical Research Center in Liver and Digestive Diseases (CIBEREHD)
Biological Laboratories Therapy Edge Spain




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.